DDInter1055 DDInter1595
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Rilpivirine is non-nucleoside reverse transcriptase inhibitor (NNRTI) which is used for the treatment of HIV-1 infections in treatment-naive patients. It is a diarylpyrimidine derivative. The internal conformational flexibility of rilpivirine and the plasticity of it interacting binding site gives it a very high potency and reduces the chance of resistance compared to other NNRTI's. Rilpivirine was developed by Tilbotec, Inc. and FDA approved on May 20, 2011. On November 21, 2017, Rilpivirine, in combination with [dolutegravir], was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named Juluca. Rilpivirine in combination with [cabotegravir] was granted FDA approval on 21 January 2021. While previously administered once-monthly only, this combination product was granted FDA approval for dosing every two months on February 01, 2022 and without the need for an oral lead-in period prior.
Levofloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Rilpivirine
Levofloxacin {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Blood creatinine increased {u} (Side Effect) is caused by {v} (Compound) Rilpivirine
Levofloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Etravirine
Etravirine {u} (Compound) resembles {v} (Compound) Rilpivirine
Levofloxacin {u} (Compound) binds {v} (Gene) CYP1A2
CYP1A2 {u} (Gene) is bound by {v} (Compound) Zafirlukast
Zafirlukast {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilpivirine
Levofloxacin {u} (Compound) causes {v} (Side Effect) Blood creatinine increased
Blood creatinine increased {u} (Side Effect) is caused by {v} (Compound) Bicalutamide
Bicalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilpivirine
Levofloxacin {u} (Compound) causes {v} (Side Effect) Immune system disorder
Immune system disorder {u} (Side Effect) is caused by {v} (Compound) Etravirine
Etravirine {u} (Compound) resembles {v} (Compound) Rilpivirine
Levofloxacin {u} (Compound) causes {v} (Side Effect) Abdominal discomfort
Abdominal discomfort {u} (Side Effect) is caused by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rilpivirine
Levofloxacin {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Metronidazole
Metronidazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rilpivirine
Levofloxacin {u} (Compound) causes {v} (Side Effect) Nephrolithiasis
Nephrolithiasis {u} (Side Effect) is caused by {v} (Compound) Pantoprazole
Pantoprazole {u} may lead to a major life threatening interaction when taken with {v} Rilpivirine
Levofloxacin {u} (Compound) causes {v} (Side Effect) Abdominal discomfort
Abdominal discomfort {u} (Side Effect) is caused by {v} (Compound) Bisacodyl
Bisacodyl {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilpivirine
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Rilpivirine (Compound)
Levofloxacin (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Rilpivirine (Compound)
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etravirine (Compound) and Etravirine (Compound) resembles Rilpivirine (Compound)
Levofloxacin (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Zafirlukast (Compound) and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Levofloxacin (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Bicalutamide (Compound) and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine
Levofloxacin (Compound) causes Immune system disorder (Side Effect) and Immune system disorder (Side Effect) is caused by Etravirine (Compound) and Etravirine (Compound) resembles Rilpivirine (Compound)
Levofloxacin (Compound) causes Abdominal discomfort (Side Effect) and Abdominal discomfort (Side Effect) is caused by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rilpivirine
Levofloxacin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rilpivirine
Levofloxacin (Compound) causes Nephrolithiasis (Side Effect) and Nephrolithiasis (Side Effect) is caused by Pantoprazole (Compound) and Pantoprazole may lead to a major life threatening interaction when taken with Rilpivirine
Levofloxacin (Compound) causes Abdominal discomfort (Side Effect) and Abdominal discomfort (Side Effect) is caused by Bisacodyl (Compound) and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine